Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Abbott Healthcare Products B.V.

🇳🇱Netherlands

Country: 🇳🇱Netherlands

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effects of Fenofibrate on Gene Expression in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Fenofibrate

First Posted Date: 2010-04-23

Last Posted Date: 2010-04-23

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 26

Registration Number: NCT01109758

Locations: 🇬🇧
Site 1, London, United Kingdom

A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: pioglitazone/rosiglitazone/placebo
Drug: rosiglitazone/pioglitazone/placebo
Drug: placebo/pioglitazone/rosiglitazone
Drug: pioglitazone/placebo/rosiglitazone
Drug: rosiglitazone/placebo/pioglitazone
Drug: placebo/rosiglitazone/pioglitazone

First Posted Date: 2010-03-17

Last Posted Date: 2010-03-17

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT01088594

Locations: 🇬🇧
S337.1.004 Site #, London, United Kingdom

Study to Investigate ADME of 14C Labeled SLV334 After an i.v. Infusion

Phase 1

Completed

Conditions: Pharmacology, Clinical

Interventions: Radiation: SLV 334

First Posted Date: 2010-01-08

Last Posted Date: 2010-09-17

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT01044524

Locations: 🇳🇱
S334.1.004 - Site 1, Zuid-Laren, Netherlands

Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure

Phase 1

Completed

Conditions: Hypogonadism

Interventions: Drug: Testosterone gel 1.62%

First Posted Date: 2009-10-21

Last Posted Date: 2009-11-25

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT00998933

Locations: 🇺🇸
Site 1, Miami Gardens, Florida, United States

Interaction Study SLV337/Simvastatin

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin
Drug: Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin

First Posted Date: 2009-06-19

Last Posted Date: 2009-09-09

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT00924430

Locations: 🇬🇧
Site 1, London, United Kingdom

First in Man Study With SLV341

Phase 1

Terminated

Conditions: Diabetes

Interventions: Drug: SLV341
Drug: placebo

First Posted Date: 2009-04-24

Last Posted Date: 2010-04-28

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 87

Registration Number: NCT00887445

Locations: 🇬🇧
S341.1.001 Site #, London, United Kingdom

Safety and Tolerability of the First IV Dosing of SLV338 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: SLV338
Drug: Placebo

First Posted Date: 2009-04-22

Last Posted Date: 2010-01-29

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT00885989

Locations: 🇬🇧
Site 1, London, United Kingdom

Effect of Fenofibrate on Sleep Apnea Syndrome

Phase 2

Terminated

Conditions: Dyslipidemia
Sleep Apnea Syndrome
Overweight
Obesity

Interventions: Drug: Placebo
Drug: Fenofibrate

First Posted Date: 2009-01-05

Last Posted Date: 2009-07-22

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT00816829

Locations: 🇫🇷
Site 1, Paris, France

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Phase 3

Completed

Conditions: Cystic Fibrosis
Pancreatic Exocrine Insufficiency

Interventions: Drug: Pancrelipase Delayed Release

First Posted Date: 2008-10-20

Last Posted Date: 2010-11-07

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT00775528

Locations: 🇺🇸
Site 11, Boise, Idaho, United States
🇺🇸
Site 5, Louisville, Kentucky, United States
🇺🇸
Site 9, Boston, Massachusetts, United States

and more 9 locations

Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure

Phase 2

Terminated

Conditions: Acute Decompensated Heart Failure; Renal Dysfunction

Interventions: Drug: SLV320
Drug: Placebo

First Posted Date: 2008-08-29

Last Posted Date: 2010-09-17

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT00744341

Locations: 🇺🇸
S320.2.011 Site # 548, Alameda, California, United States
🇺🇸
S320.2.011 Site # 566, Banning, California, United States
🇺🇸
S320.2.011 Site # 551, Inglewood, California, United States

and more 102 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy